End of an era, page-4

And, here is ZLD extract from James Dunn's story in the Switzer Report (22 June 2020)

1. Zelira Therapeutics (ZLD, 5.6 cents)

Market capitalisation: $54 million

FY19 revenue: nil

Net profit: –$3.6 million

Three-year return: –10.8% a year

Zelira has one foot on the conventional

pharmaceutical side and one foot on the

over-the-counter healthcare market. In the former, its

patented medicinal cannabis formulation, ZLT-101, is

coming off a successful clinical trial against chronic

insomnia, which means Zelira is poised to launch the

world’s first clinically validated medicinal marijuana

formulation for insomnia into global markets in 2020.

To put this in context, at present there are only two

registered cannabis medicines in the world, Epidiolex

for epilepsy and the nose spray Sativex, for multiple

sclerosis spasticity, both owned by UK company GW

Pharma.

The company is also conducting a Phase 1 clinical

trial in patients experiencing long-term chronic pain.

Cannabinoid-based medication can potentially

provide an alternative treatment to opioids for chronic

pain, but the epidemic of opioid addiction has

clinicians looking for a non-drug treatment. Zelira also

has a clinical trial programs focused on insomnia and

autism.

Zelira also has a pre-clinical research program

examining the effect of cannabinoids in breast, brain

and pancreatic cancer; as well as research examining

the potential for cannabinoids to treat

diabetes-associated cognitive decline.

Zelira has also launched a pharmaceutical-grade

medicinal cannabis product called HOPE, which was

developed to specifically address patient symptoms

associated with Autism Spectrum Disorder. It was

launched in the US in May 2019 and is also being

sold in Germany and the UK; it will be launched in

Australia and Asia-Pacific later this year. The

company’s other proprietary product, CAN-001, is

being developed for the treatment of

chemotherapy-induced nausea and vomiting (CINV),

which occurs in approximately 80% of the new 23.6

million cases of cancer annually worldwide. From its

platform Zelira also plans to introduce products in

age-related disorders, oral healthcare and

dermatology.

Zelira has only just started earning revenue; but

against that, it will shortly be one of the few

companies in the world with an actual cannabis

medicine, that has passed clinical trials, launched into

global markets for a major unmet need.